Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AQST with free AI briefings, catalyst countdowns, and dilution alerts.

AQST · Aquestive Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90.3M Cash on Hand
32.9mo Cash Runway
24.4% Short Interest
$9.33 Analyst Target (9)
Follow AQST by email Get an email when AQST reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AQST, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-03-16 Anaphylm (dibutepinephrine) NDA 71% ±67% by Mar 19
2027-03-23 Libervant (unnamed licensee) patients twelve years of age and older NDA 66% ±60% by May 21
2027-03-29 Libervant patients six to eleven years of age NDA 66% ±60% by May 21

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What AQST Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15… Epilepsy Phase 3 · NCT03428360 Completed
DESF Allergic Reaction Phase 2 · NCT06527937 Completed
Diastat® Rectal Gel (Valeant Pharmaceuticals… Epilepsy Phase 1/2 · NCT03953820 Completed
Diazepam Buccal Film Epilepsy Phase 2 · NCT03222349 Completed
Epinephrine Injection Allergic Reaction Phase 2 · NCT06527937 Completed
Riluzole Oral Soluble Film ALS Phase 2 · NCT03457753 Withdrawn
Riluzole Oral Soluble film (ROSF) 50 mg Amyotrophic Lateral Sclerosis Phase 2 · NCT03679975 Terminated
Ondansetron 8 mg ODFS with water Healthy Participants Phase 1 · NCT01220167 Completed
Ondansetron 8 mg ODFS without water Healthy Participants Phase 1 · NCT01220167 Completed
Zofran ODT (ondansetron 8 mg) without water Healthy Participants Phase 1 · NCT01220167 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AQST holds $90.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.2M/quarter from operations, an estimated runway of 32.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AQST files for a raise →

👥 Who Owns AQST

Insiders 2.1% Other 5%+ holders 7.5% Institutions (244 holders) 58.1% Public and other holders 32.3%
HolderTypeShares% of sharesAs of
Bratton Capital Management, LP Institution (13F) 9,810,958 7.81% 2026-09-30
Bass Edward P 5%+ holder (13G) 9,385,561 7.47% 2026-10-07
BlackRock, Inc. Institution (13G, 5%+) 7,992,647 6.36% 2026-06-30
RTW Investments LP Institution (13F) 7,426,471 5.91% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 4,784,202 3.81% 2026-09-30
State Street Corporation Institution (13F) 3,481,391 2.77% 2026-09-30
Federated Hermes, Inc. Institution (13F) 3,197,861 2.54% 2026-09-30
Geode Capital Management, LLC Institution (13F) 2,895,633 2.30% 2026-09-30
Samsara BioCapital, LLC Institution (13F) 2,434,367 1.94% 2026-09-30
Rosalind Advisors, Inc. Institution (13F) 2,000,000 1.59% 2026-09-30
HRT Financial LP Institution (13F) 1,801,675 1.43% 2026-09-30
Daniel Barber
President and CEO, Director · +816,100 options
Insider 627,317 0.50% 2026-10-15

Share count 125,687,705 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-12
Davis Matthew W.
Tax withholding (F) 5,303 $3.52 94,697
2026-11-10
filed 2026-11-12
Daly Richard J
Purchase (P) 1,200 $3.53 1,200
2026-11-10
filed 2026-11-12
Daly Richard J
Purchase (P) 26,825 $3.55 28,025
2026-11-06
filed 2026-11-10
Daly Richard J
Option award (A) 57,000 – –
2026-10-21
filed 2026-10-23
Cochran John
Other (J) 62,229 – 161,715

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-01-31 Anaphylm NDA -53.8% +39% +39.3%
2025-11-06 — NDA +0.5% +2.2% -7%
2025-10-08 Anaphylm NDA +19.2% +3.9% +15.2%

Browse all historical PDUFA outcomes →

Get the full AQST picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AQST and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.